WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a time when sustainability has become what the Company believes a defining challenge for the biotechnology industry.

Tevogen reported a loss from operations calculated in accordance with U.S. GAAP of $5.7 million for the three months ended September 30, 2025, a reduction of 6% as compared to the three months ended September 30, 2024. The Company reported a 51% reduction in operating loss, totaling $21.5 million for the nine months ended September 30, 2025, compared to the same period in 2024.

Tevogen Bio Holdings Inc. Unaudited Consolidated Statements of Operations

 

 

Three months ended September 30,

 

 

Nine months ended September 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

3,110,752

 

 

$

3,260,938

 

 

$

9,005,811

 

 

$

28,196,970

 

General and administrative

 

 

2,618,679

 

 

$

2,824,589

 

 

 

12,524,503

 

 

 

16,004,308

 

Total operating expenses

 

 

5,729,431

 

 

 

6,085,527

 

 

 

21,530,314

 

 

 

44,201,278

 

Loss from operations

 

 

(5,729,431

)

 

 

(6,085,527

)

 

 

(21,530,314

)